Sponsor study identifier
Secondary identifiers
interventional
197
1 country
1
Study Start
February 27, 2003
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
February 2, 2015
Actual (reported)Study Completion
February 2, 2015
Actual (reported)This study looks at the role of a specific brain chemical system in the mood and attention symptoms seen in major depression and bipolar disorders using functional brain imaging.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
February 2, 2015
Actual (reported)Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
February 27, 2003
Date type not reportedThis date has not been verified as actual or estimated.
March 6, 2003
Actual (reported)March 6, 2003
Actual (reported)February 2, 2015
Actual (reported)February 2, 2015
Actual (reported)Evaluation of the antidepressant effects of the antimuscarinic agent scopolamine
5 to 10 years
National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, 20892, United States
Elliott R, Rubinsztein JS, Sahakian BJ, Dolan RJ. Selective attention to emotional stimuli in a verbal go/no-go task: an fMRI study. Neuroreport. 2000 Jun 5;11(8):1739-44. doi: 10.1097/00001756-200006050-00028.
Murphy FC, Sahakian BJ, Rubinsztein JS, Michael A, Rogers RD, Robbins TW, Paykel ES. Emotional bias and inhibitory control processes in mania and depression. Psychol Med. 1999 Nov;29(6):1307-21. doi: 10.1017/s0033291799001233.
Carlos A Zarate, M.D.
National Institute of Mental Health (NIMH)
197 participants (actual enrollment reported by the registry).
First Submitted
March 6, 2003
First Posted
March 6, 2003
Study Start
February 27, 2003
Date type not reportedThis date has not been verified as actual or estimated.
Scopolamine in Bipolar Depression
Contact the study team to confirm eligibility.
Murray LA, Whitehouse WG, Alloy LB. Mood congruence and depressive deficits in memory: a forced-recall analysis. Memory. 1999 Mar;7(2):175-96. doi: 10.1080/741944068.
Furey ML, Drevets WC, Hoffman EM, Frankel E, Speer AM, Zarate CA Jr. Potential of pretreatment neural activity in the visual cortex during emotional processing to predict treatment response to scopolamine in major depressive disorder. JAMA Psychiatry. 2013 Mar;70(3):280-90. doi: 10.1001/2013.jamapsychiatry.60.
Primary Completion
February 2, 2015
Actual (reported)Study Completion
February 2, 2015
Actual (reported)Last Updated
March 22, 2021
Record last verified: 2015-02-02
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: